The 118 A > G polymorphism in the human µ‐opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease

“Mini-mental state”

1975 • 82,784 citations

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

1993 • 14,121 citations

The use of the nitrogen mustards in the palliative treatment of carcinoma.With particular reference to bronchogenic carcinoma

1948 • 2,185 citations

Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases

1983 • 1,540 citations

When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function

1995 • 1,433 citations

The LightCycler ^TM : A Microvolume Multisample Fluorimeter with Rapid Temperature Control

1997 • 908 citations

Pain Measurement Tools and Methods in Clinical Research in Palliative Care

2002 • 418 citations

Opioid rotation for toxicity reduction in terminal cancer patients

1995 • 390 citations

Morphine-6-glucuronide, a potent mu agonist

1987 • 365 citations

The Norwegian Brief Pain Inventory Questionnaire

2002 • 302 citations

Sequence variability and candidate gene analysis in complex disease: association of micro opioid receptor gene variation with substance dependence

2000 • 291 citations

Switching From Morphine to Methadone to Improve Analgesia and Tolerability in Cancer Patients: A Prospective Study

2001 • 251 citations

Analgesic effects of morphine and morphine‐6‐glucuronide in a transcutaneous electrical pain model in healthy volunteers

2003 • 222 citations

The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine

2002 • 208 citations

Incomplete cross tolerance and multiple mu opioid peptide receptors

2001 • 208 citations

Oral morphine in cancer pain: influences on morphine and metabolite concentration

1990 • 163 citations

Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6beta-glucuronide antinociception.

1997 • 154 citations

Opioid receptor and peptide gene polymorphisms: potential implications for addictions

2000 • 153 citations

Does the A118G Polymorphism at the μ-opioid Receptor Gene Protect against Morphine-6-Glucuronide Toxicity?

2002 • 144 citations

The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function

1992 • 135 citations

Morphine, Morphine-3-Glucuronide, Morphine-6-Glucuronide, and 6-Monoacetylmorphine Determined by Means of Atmospheric Pressure Chemical Ionization-Mass Spectrometry-Liquid Chromatography in Body Fluids of Heroin Victims

1997 • 98 citations

The Transfer Half-life of Morphine-6-glucuronide from Plasma to Effect Site Assessed by Pupil Size Measurement in Healthy Volunteers

2001 • 95 citations

Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine

2000 • 87 citations

Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain

1996 • 68 citations

Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients

2003 • 60 citations

Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: A prospective survey in 300 adult cancer patients

2003 • 55 citations

No contribution of morphine-6-glucuronide to clinical morphine effects after short-term administration.

1998 • 21 citations

When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function.

1995 • 1 citations